Olivia El Naggar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Olivia El Naggar has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Gabriele Romano
Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania
19 shared publications - Alexander Joseph Lazar
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
18 shared publications - Francesca Paradiso
BostonGene Corporation, Waltham, Massachusetts
18 shared publications - Francesca Taraballi
Center for Musculoskeletal Regeneration, Houston Methodist Academic Institute, Houston, TX 77030, USA
18 shared publications - James C. Costello
Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, USA
18 shared publications - Jennifer Ann Wargo
The University of Texas MD Anderson Cancer Center
18 shared publications
Latest Publications
- 19 August 2026
- Published by Drexel University Libraries
Exploiting tumor microenvironment-mediated mechanisms of therapeutic resistance in Ras/MAPK-altered solid cancers
Ras/MAPK alterations drive roughly 40% of human cancers which vary in phenotype, aggressiveness, and response to therapy. This thesis asks how oncogenic Ras/MAPK signaling interacts with distinct components of the tumor microenvironment to drive therapy resistance in two cancer types. The negative regulator of Ras, Neurofibromin 1 (NF1), is altered in about 20% of tubo-ovarian high-grade serous carcinomas (HGSC). We use in vitro and in vivo models of ovarian cancer to study how cell-cell interactions between adipocytes and cancer cells impact therapy response. NF1 alteration exacerbates adipocyte-mediated resistance to standard-of-care chemotherapy. Downstream of Ras, activating mutations in the BRAF kinase are present in over half of cutaneous melanoma cases. Specifically, BRAF^[V600E] hyperactivates downstream MAPK signaling, which is the target of several generations of small-molecule inhibitors. MAPK-targeted therapies show initial efficacy in patients, but acquired resistance is a major clinical threat. Focusing on the role of the immune compartment in treatment-refractory melanoma, we show that targeting the novel immune checkpoint, P-selectin glycoprotein ligand-1 (PSGL-1), delays relapse to BRAF/MEK-targeted therapy in pre-clinical models. Combined BRAF/MEK and PSGL-1 targeting provides a durable anti-tumor response through enhanced functionality and a memory-like phenotype in CD8⁺ T cell subsets. Together, these studies address how tumor-cell intrinsic and extrinsic factors interact under the selective pressure of therapy in Ras/MAPK-altered solid tumors. We provide insight on how genetic alterations affect interactions between cancer cells and their environment and how these dynamics reveal resistance mechanisms that can be exploited for therapeutic benefit.
- 19 August 2026
- Published by Drexel University Libraries
Exploiting tumor microenvironment-mediated mechanisms of therapeutic resistance in Ras/MAPK-altered solid cancers
Ras/MAPK alterations drive roughly 40% of human cancers which vary in phenotype, aggressiveness, and response to therapy. This thesis asks how oncogenic Ras/MAPK signaling interacts with distinct components of the tumor microenvironment to drive therapy resistance in two cancer types. The negative regulator of Ras, Neurofibromin 1 (NF1), is altered in about 20% of tubo-ovarian high-grade serous carcinomas (HGSC). We use in vitro and in vivo models of ovarian cancer to study how cell-cell interactions between adipocytes and cancer cells impact therapy response. NF1 alteration exacerbates adipocyte-mediated resistance to standard-of-care chemotherapy. Downstream of Ras, activating mutations in the BRAF kinase are present in over half of cutaneous melanoma cases. Specifically, BRAF^[V600E] hyperactivates downstream MAPK signaling, which is the target of several generations of small-molecule inhibitors. MAPK-targeted therapies show initial efficacy in patients, but acquired resistance is a major clinical threat. Focusing on the role of the immune compartment in treatment-refractory melanoma, we show that targeting the novel immune checkpoint, P-selectin glycoprotein ligand-1 (PSGL-1), delays relapse to BRAF/MEK-targeted therapy in pre-clinical models. Combined BRAF/MEK and PSGL-1 targeting provides a durable anti-tumor response through enhanced functionality and a memory-like phenotype in CD8⁺ T cell subsets. Together, these studies address how tumor-cell intrinsic and extrinsic factors interact under the selective pressure of therapy in Ras/MAPK-altered solid tumors. We provide insight on how genetic alterations affect interactions between cancer cells and their environment and how these dynamics reveal resistance mechanisms that can be exploited for therapeutic benefit.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma
Supplementary Tables from Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma
Supplementary Tables from Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S6-S10 from Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma
Supplementary Figures S6-S10 from Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S6-S10 from Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma
Supplementary Figures S6-S10 from Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S5 from Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S5 from Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma
Patients with BRAF-mutant melanoma show substantial responses to combined BRAF and MEK inhibition, but most relapse within 2 years. A major reservoir for drug resistance is minimal residual disease (MRD), comprised of drug-tolerant tumor cells laying in a dormant state. Towards exploiting potential therapeutic vulnerabilities of MRD, we established a genetically engineered mouse model of BrafV600E-driven melanoma MRD wherein genetic BrafV600E extinction leads to strong but incomplete tumor regression. Transcriptional time-course analysis after BrafV600E extinction revealed that after an initial surge of immune activation, tumors later became immunologically “cold” after MRD establishment. Computational analysis identified candidate T-cell recruiting chemokines as strongly upregulated initially and steeply decreasing as the immune response faded. Therefore, we hypothesized that sustaining chemokine signaling could impair MRD maintenance through increased recruitment of effector T cells. We found that intratumoral administration of recombinant Cxcl9 (rCxcl9), either naked or loaded in microparticles, significantly impaired MRD relapse in BRAF-inhibited tumors, including several complete pathologic responses after microparticle-delivered rCxcl9 combined with BRAF and MEK inhibition. Our experiments constitute proof of concept that chemokine-based microparticle delivery systems are a potential strategy to forestall tumor relapse and thus improve the clinical success of first-line treatment methods.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma
Patients with BRAF-mutant melanoma show substantial responses to combined BRAF and MEK inhibition, but most relapse within 2 years. A major reservoir for drug resistance is minimal residual disease (MRD), comprised of drug-tolerant tumor cells laying in a dormant state. Towards exploiting potential therapeutic vulnerabilities of MRD, we established a genetically engineered mouse model of BrafV600E-driven melanoma MRD wherein genetic BrafV600E extinction leads to strong but incomplete tumor regression. Transcriptional time-course analysis after BrafV600E extinction revealed that after an initial surge of immune activation, tumors later became immunologically “cold” after MRD establishment. Computational analysis identified candidate T-cell recruiting chemokines as strongly upregulated initially and steeply decreasing as the immune response faded. Therefore, we hypothesized that sustaining chemokine signaling could impair MRD maintenance through increased recruitment of effector T cells. We found that intratumoral administration of recombinant Cxcl9 (rCxcl9), either naked or loaded in microparticles, significantly impaired MRD relapse in BRAF-inhibited tumors, including several complete pathologic responses after microparticle-delivered rCxcl9 combined with BRAF and MEK inhibition. Our experiments constitute proof of concept that chemokine-based microparticle delivery systems are a potential strategy to forestall tumor relapse and thus improve the clinical success of first-line treatment methods.
- 17 November 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 455 (1) , 114828
Timeless prevents senescence-associated phenotypes and enhances DNA repair to promote esophageal cancer cell growth
- 17 November 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 455 (1) , 114828
Timeless prevents senescence-associated phenotypes and enhances DNA repair to promote esophageal cancer cell growth
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
Supplementary Tables from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
Supplementary Tables from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S6-S10 from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
Supplementary Figures S6-S10 from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S6-S10 from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
Supplementary Figures S6-S10 from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
Supplementary Tables from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
Supplementary Tables from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S6-S10 from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
Supplementary Figures S6-S10 from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S6-S10 from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
Supplementary Figures S6-S10 from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma